VASOPHARM ANNOUNCES RESULTS OF THE NOSTRA III TRAUMATIC BRAIN INJURY PHASE III STUDY

vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announces that the NOSTRA III traumatic brain injury (TBI) Phase III clinical trial of ronopterin (VAS203) did not meet the pre-specified primary endpoint of improvement in extended Glasgow Outcome Scale (eGOS) at six months after trauma. Importantly, hypothesis driven post-hoc analysis reveals a statistically significant and clinically meaningful increase in eGOS over time in patients with moderate and severe TBI when ronopterin is infused within 12 hours after trauma.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH